XOPENEX
LOE ApproachingNDAINHALATIONSOLUTION
Approved
Mar 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
XOPENEX by Hikma is 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3', 5'-adenosine monophosphate (cyclic amp). First approved in 1999.
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XOPENEX (levalbuterol) is an inhaled bronchodilator solution containing the active R-enantiomer of albuterol, a beta-2 adrenergic agonist. It treats acute bronchospasm and airway obstruction in patients with reversible obstructive airway disease by activating beta-2 receptors on airway smooth muscle, increasing cyclic AMP and inducing muscle relaxation. The drug also inhibits mast cell mediator release, providing functional antagonism against multiple bronchoconstrictor triggers.
$0.005BPart D
LOE ApproachingMinimal market presence with only $5K in Part D spending signals a niche product facing imminent loss of exclusivity, indicating small brand teams and limited career growth opportunities.
Mechanism of Action
2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3', 5'-adenosine monophosphate (cyclic AMP). The increase in cyclic AMP is associated with the activation of protein kinase A, which in turn,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on XOPENEX at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.